South Korea
· Delayed Price · Currency is KRW Genomictree Statistics
Total Valuation
Genomictree has a market cap or net worth of KRW 552.97 billion. The enterprise value is 459.00 billion.
| Market Cap | 552.97B |
| Enterprise Value | 459.00B |
Important Dates
The next estimated earnings date is Tuesday, March 18, 2025.
| Earnings Date | Mar 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Genomictree has 23.99 million shares outstanding. The number of shares has increased by 9.48% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 23.99M |
| Shares Change (YoY) | +9.48% |
| Shares Change (QoQ) | -2.52% |
| Owned by Insiders (%) | 16.05% |
| Owned by Institutions (%) | 5.34% |
| Float | 20.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 249.33 |
| PB Ratio | 4.46 |
| P/TBV Ratio | 4.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -46.27 |
| EV / Sales | 208.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -31.50 |
Financial Position
The company has a current ratio of 19.27, with a Debt / Equity ratio of 0.02.
| Current Ratio | 19.27 |
| Quick Ratio | 19.05 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.14 |
| Interest Coverage | -51.52 |
Financial Efficiency
Return on equity (ROE) is -8.11% and return on invested capital (ROIC) is -7.14%.
| Return on Equity (ROE) | -8.11% |
| Return on Assets (ROA) | -6.78% |
| Return on Capital (ROIC) | -7.14% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.02 |
| Inventory Turnover | 6.11 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +37.93% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +37.93% |
| 50-Day Moving Average | 17,179.00 |
| 200-Day Moving Average | 19,565.05 |
| Relative Strength Index (RSI) | 68.94 |
| Average Volume (20 Days) | 839,544 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genomictree had revenue of KRW 2.20 billion and -9.92 billion in losses. Loss per share was -548.86.
| Revenue | 2.20B |
| Gross Profit | -915.07M |
| Operating Income | -14.66B |
| Pretax Income | -10.76B |
| Net Income | -9.92B |
| EBITDA | -13.48B |
| EBIT | -14.66B |
| Loss Per Share | -548.86 |
Balance Sheet
The company has 96.22 billion in cash and 2.01 billion in debt, giving a net cash position of 94.21 billion or 3,926.93 per share.
| Cash & Cash Equivalents | 96.22B |
| Total Debt | 2.01B |
| Net Cash | 94.21B |
| Net Cash Per Share | 3,926.93 |
| Equity (Book Value) | 124.33B |
| Book Value Per Share | 5,173.07 |
| Working Capital | 92.85B |
Cash Flow
In the last 12 months, operating cash flow was -12.12 billion and capital expenditures -2.45 billion, giving a free cash flow of -14.57 billion.
| Operating Cash Flow | -12.12B |
| Capital Expenditures | -2.45B |
| Free Cash Flow | -14.57B |
| FCF Per Share | -607.38 |
Margins
| Gross Margin | -41.60% |
| Operating Margin | -666.28% |
| Pretax Margin | -489.11% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genomictree does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.48% |
| Shareholder Yield | -9.48% |
| Earnings Yield | -2.38% |
| FCF Yield | -2.64% |
Stock Splits
The last stock split was on September 14, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Sep 14, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Genomictree has an Altman Z-Score of 35.2.
| Altman Z-Score | 35.2 |
| Piotroski F-Score | n/a |